For following the competition: what moved in each program, several studies read as one move.
- efgartigimod alfa
- ianalumab
- rilzabrutinib
- + 34 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Purpura, Thrombocytopenic, Idiopathic to watchlistEvery Monday by email · turn it off any timePro · free during the beta